Indication: TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody...

Read more

Indication: TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.

Read less
Severe Active Disease
  • Severe vasculitis is defined by American College of Rheumatology/Vasculitis Foundation (ACR/VF) guidelines as having life-threatening or organ-threatening manifestations2
  • Active vasculitis is defined by ACR/VF guidelines as new, persistent or worsening signs and/or symptoms attributed to GPA or MPA and not related to prior damage2
Identifying Patients

Approximately 80%-90% of patients with AAV present with renal or other organ-threatening disease activity, which can be considered severe active disease1,2

Patients in the ADVOCATE trial presented with a spectrum of clinical manifestations.3,4

General

Myalgia, arthralgia, fever, weight loss5,6

ADVOCATE: 68.2% general involvement3